FOLH1 and prostate carcinoma: Consequently, 68Ga-PSMA PET/CT has a high impact on the management of biochemically recurrent prostate cancer as assessed by several retrospective and prospective analyses leading to changes in treatment in more than half of patients with biochemical recurrence (7, 8).